A. C. Walls

The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.

This study uses deep mutational scanning to analyze how mutations in the Omicron BA.1 and BA.2 RBDs affect ACE2 binding, RBD folding, and antibody escape, identifying epistatic shifts and lineage-specific changes.

This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

This study evaluates neutralizing activity against Omicron BA.1 and BA.2 variants elicited by various vaccines and finds that booster doses enhance neutralizing titers and breadth across all vaccine platforms.

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

The paper examines structural changes in the SARS-CoV-2 spike E406W mutant that reduce neutralization by a monoclonal antibody cocktail and alters epitope recognition.

This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.

This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.

The paper examines antibody responses in Delta breakthrough infections, finding they are more potent, durable, and broad compared to vaccinated-only or infected-only individuals.

The paper determines the structure of the CCoV-HuPn-2018 spike glycoprotein, identifies its receptor, and shows cross-neutralizing antibodies against related coronaviruses.

This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.

This study traces the evolutionary history of ACE2 binding in sarbecoviruses, finding it is an ancestral trait that has been lost in some clades and is highly evolvable through single amino-acid mutations.

This paper designs stabilized SARS-CoV-2 RBD variants using deep mutational scanning and structure-based design, showing improved thermal stability and manufacturability for vaccine applications.

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.

This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.

This study identifies membrane lectins that enhance SARS-CoV-2 infection and show how different antibodies neutralize infection through distinct mechanisms.

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.

This study identifies a monoclonal antibody that broadly neutralizes multiple beta-coronaviruses by targeting a conserved epitope, providing a structural basis for designing pan-coronavirus vaccines.

The paper designs modular nanocages that assemble antibodies into precise geometries, enhancing signaling and neutralization compared to free antibodies.

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

The paper experimentally measures the effects of all amino-acid mutations in the SARS-CoV-2 RBD on protein folding and ACE2 binding, identifying constrained regions and tolerated mutations.

This paper designs a stabilized SARS-CoV-2 spike glycoprotein in the closed conformation, showing it maintains structure and antigenicity while being applicable to other beta-coronaviruses.

This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.

This study characterizes the structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, showing its receptor-binding properties, furin cleavage site, and potential for cross-neutralizing antibodies.